Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.

Scientific reports - 17 Jan 2018

Caiola Elisa, Frapolli Roberta, Tomanelli Michele, Valerio Rossana, Iezzi Alice, Garassino Marina C, Broggini Massimo, Marabese Mirko

Abstract excerpt

Non-Small-Cell Lung Cancer (NSCLC) is a poorly chemosensitive tumor and targeted therapies are only used for about 15% of patients where a specific driving and druggable lesion is observed (EGFR, ALK, ROS). KRAS is one of the most frequently mutated genes in NSCLC and patients harboring these mutations do not benefit from specific treatments. Sorafenib, a multi-target tyrosine kinase inhibitor, was proposed as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Proto-Oncogene Proteins p21(ras)
Share to Niacinamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenylurea Compounds

Share to Protein-Tyrosine Kinases

Share to Pyrazoles

Share to Pyrimidines

Share to Pyrimidinones

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 29343688
DOI: 10.1038/s41598-017-18900-y
PMCID: PMC5772438

Genes

KRAS
ALK
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.PMID 29343688Read ↗

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancerSemantic proximity Read ↗

Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.Semantic proximity Read ↗

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung CancerSemantic proximity Read ↗

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.Semantic proximity Read ↗

Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.Semantic proximity Read ↗

A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.Semantic proximity Read ↗

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibitionSemantic proximity Read ↗

Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.Semantic proximity Read ↗

Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.Semantic proximity Read ↗

Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulationSemantic proximity Read ↗

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.